Benefits and risks of therapeutic alternatives for macrolide resistant Mycoplasma Pneumoniae pneumonia in children.

Benefits and risks of therapeutic alternatives for macrolide resistant Mycoplasma Pneumoniae pneumonia in children. Korean J Pediatr. 2019 Mar 15;: Authors: Yang HJ Abstract Mycoplasma pneumoniae pneumonia (MPP) has been generally susceptible to macrolides, however emergence of macrolide-resistant Mycoplasma pneumoniae pneumonia (MRMP) has made the treatment of MPP challenging. MRMP rapidly spread after 2000s, especially in the Eastern Asia. MRMPs are more common in children and adolescents than in adults, which is likely related to the frequent use of macrolides for treatments of MP infections in children. The MRMP is unlikely to be related with clinical, laboratory, or radiological- severity, although it is likely to cause longer persistence of symptoms and length of hospital stay. Thereby, it causes an increased burden of disease and poor quality or life in the patients' aspect, and socioeconomic burden in the society as well. Up to date, the only alternative options for the treatment of MRMP are secondary antimicrobials such tetracyclines (TCs) or fluoroquinolones (FQs) or systemic corticosteroids (SCs), however the former are contraindicated in children due to the concerns of potential adverse events (i.e., tooth discoloration or tendinopathy). Few guidelines recommended TCs or FQs as second-line drug of choice in the treatment of the MRMP. However, there has been no evidence-based guideline. Furthermore, safety issues have not ...
Source: Korean Journal of Pediatrics - Category: Pediatrics Tags: Korean J Pediatr Source Type: research